The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder)
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment; Note: Subjects with a history of early stage or locally advanced non-metastatic prostate cancer within 2 years of the start of study treatment may be included in the study
No malignancy (other than the one treated in this study) which required radiotherapy or systemic treatment within the past 5 years
Subject has another malignancy for which treatment is required.
Concurrent diagnosis of another malignancy if either systemic treatment or surgery is expected to be required within 2 years from study entry
Evidence within the last 2 years of another malignancy which required systemic treatment
Evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
Subject has a history of a malignancy (other than the disease under treatment in the study) within 5 years before first study treatment administration
The subject has had within 2 years before the start of study treatment evidence of another malignancy which required systemic treatment
Presence of malignancy (other than the one treated in this study) which required systemic treatment within the past 3 years
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
No malignancy (other than for which patient underwent transplant) which required radiotherapy or systemic treatment within the past 5 years
The participant has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment
